Impact Biomedical’s Laetose Technology Advances with U.S. Patent Allowance for Low Glycemic Sugar Composition

In a groundbreaking development, Impact Biomedical Inc. (IBIO), a company in which DSS Inc. holds a significant investment, has achieved a major milestone with its proprietary Laetose technology platform. This exciting breakthrough comes in the form of a U.S. Patent Allowance, with the U.S. Patent and Trademark Office (USPTO) recently granting the company patent 11,898,184. Titled Low Glycemic Sugar Composition, this patent represents a significant advancement within the Laetose platform, further solidifying Impact Biomedical s position as a leading innovator in the field. Fact 1: USPTO Issues Patent for Low Glycemic Sugar CompositionThe newly granted U.S. patent showcases Impact Biomedical s dedication to developing and commercializing unique solutions. This patent revolves around the creation of a Low Glycemic Sugar Composition, which is a result of the innovative Laetose technology platform. Laetose aims to provide alternative sugar options that have a minimal impact on blood sugar levels, catering to the growing demand for healthier and diabetic-friendly sweeteners.Fact 2: Significance of the Laetose PlatformLaetose technology represents an exciting prospect for Impact Biomedical, as it has the potential to revolutionize the way we approach sugar consumption. By developing low glycemic sugar compositions, the company addresses the challenges and concerns associated with traditional sugar alternatives. This breakthrough has the potential to have a transformative impact on the food and beverage industry, offering consumers healthier options without compromising on taste.

Comments